Short answer
Humacyte, Inc. (HUMA) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal Q3 2026 results for quarter ended September 30, 2026.
Humacyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal Q3 2026 results for quarter ended September 30, 2026
- Humacyte press release furnished as Exhibit 99.1, containing the detailed financial results
- Results announcement gives investors an update on operating performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Symvess Q3 sales $1.0M, up 151% sequentially and 45% year over year, with ordering hospitals rising 44% to 49
- October sales reached $0.8M, while management targets at least doubling Q3 sales in Q4, supporting commercial traction but raising execution expectations
- Product revenue $1.023M versus cost of goods sold $1.429M, indicating negative gross margin during early commercialization
- Cash and restricted cash $64.9M, with nine-month operating cash burn $62.1M, highlighting continuing financing risk despite lower R&D spending
- Planned November 2026 sBLA filing for dialysis access and newly initiated Phase 2a CABG study expand catalysts, but both remain regulatory or clinical-stage opportunities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Humacyte, Inc. 8-K filings
Get the next HUMA 8-K as it lands
Follow HUMA for push alerts, or ask the research agent what this filing means.